CE Mark Approval Received for New 26 mm and 29 mm Valves MINNEAPOLIS - Medtronic plc today announced CE (Conformité Européene) Mark for the 26 mm and 29 mm sizes of the CoreValve® Evolut(TM) R System, ...

PARIS – A month earlier than expected, Dublin-based Medtronic plc said it has received the CE mark for the Corevalve Evolut R 34 millimeter transcatheter aortic valve implantation (TAVI). The ...

Medtronic is kicking off the nationwide rollout of the latest generation of its transcatheter aortic valve replacement system, the Evolut FX. The TAVR implant first received approval to treat aortic ...

Next-Generation TAVI System Offers Ability to Recapture and Reposition During Deployment MINNEAPOLIS - Medtronic, Inc. today announced CE (Conformité Européene) Mark for the 23 mm CoreValve® Evolut(TM ...

DUBLIN, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), a global leader in heart valve therapies, today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the ...

Medtronic plc MDT recently presented the complete two-year outcome from its Evolut Low Risk Trial virtually at the EuroPCR 2021 e-Course. This outcome demonstrated Medtronic’s Evolut transcatheter ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...

Medtronic announced US Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX TAVR system. Designed to ...

Nearly two years after the FDA opened up minimally invasive aortic heart valve replacements to younger, healthier people more likely to make it through open surgery with fewer complications, Medtronic ...

The US Food and Drug Administration has approved Medtronic's Evolut FX system for transcatheter aortic valve replacement (TAVR) in patients with symptomatic severe aortic stenosis at all risk levels.